CLINICAL TRIALS PROFILE FOR ABATACEPT
✉ Email this page to a colleague
All Clinical Trials for abatacept
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00048568 ↗ | A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | Completed | Bristol-Myers Squibb | Phase 3 | 2002-12-01 | Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied. Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued. |
| NCT00048581 ↗ | Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | Completed | Bristol-Myers Squibb | Phase 3 | 2002-12-01 | The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study. |
| NCT00048932 ↗ | A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2002-12-01 | The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications. |
| NCT00095147 ↗ | Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2005-02-01 | The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo. |
| NCT00095173 ↗ | BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2003-12-01 | The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare. |
| NCT00119678 ↗ | Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone | Completed | Bristol-Myers Squibb | Phase 2 | 2005-09-01 | The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). All participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied. |
| NCT00122382 ↗ | Remission and Joint Damage Progression in Early Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2005-07-01 | This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for abatacept
Condition Name
Clinical Trial Locations for abatacept
Trials by Country
Clinical Trial Progress for abatacept
Clinical Trial Phase
Clinical Trial Sponsors for abatacept
Sponsor Name
